HighTower Advisors
TRIB

HighTower Advisors’s Trinity Biotech TRIB Stock Holding History

HighTower Advisors’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,200
Closed -$129K – 2018
2016
Q1 		$129K Hold
2,200
– – ﹤0.01% 1882
2015
Q4 		$131K Buy
+2,200
New +$130K ﹤0.01% 1821

Other funds holding TRIB

Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

HighTower Advisors's TRIB Position: Q2 2016 in Review

HighTower Advisors sold out of Trinity Biotech (TRIB) in Q2 2016, closing a stake of 2,200 shares — an estimated $129K sold.

HighTower Advisors first reported a position in TRIB in Q4 2015 and held it in 2 quarters. The position peaked at $131K in Q4 2015. 79 funds tracked by Wall St. Rank hold TRIB as of Q2 2016.

  • HighTower Advisors reported no remaining Trinity Biotech position as of Q2 2016 after selling out during the quarter.
  • HighTower Advisors sold 2,200 Trinity Biotech shares in Q2 2016, an estimated $129K.
  • HighTower Advisors first reported a position in Trinity Biotech in Q4 2015 and held it in 2 quarters.
  • HighTower Advisors's Trinity Biotech position peaked at $131K in Q4 2015.
  • 79 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2016.

Based on HighTower Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.